Paper Details

  1. Home
  2. Paper Details

Efficacy and Safety of Ranibizumab 0.5 mg for the Treatment of Macular Edema Resulting from Uncommon Causes: Twelve-Month Findings from PROMETHEUS.

Author: , BhaumikAmitabha, HykinPhilip G, LaiTimothy Y Y, LiJun, MitchellPaul, StaurenghiGiovanni, WenzelAndreas, WolfSebastian

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Ranibizumab showed superiority in BCVA gain over sham in treating ME due to uncommon causes.
Paper Details　
Original Abstract of the Article :
PURPOSE: To evaluate the efficacy and safety of ranibizumab 0.5 mg in adult patients with macular edema (ME) resulting from any cause other than diabetes, retinal vein occlusion, or neovascular age-related macular degeneration. DESIGN: A phase 3, 12-month, double-masked, randomized, sham-controlled...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ophtha.2017.12.002

データ提供：米国国立医学図書館（NLM）

Efficacy and Safety of Ranibizumab 0.5 mg for Macular Edema: A 12-Month Study

Navigating the intricate world of ophthalmic diseases is akin to navigating a desert landscape filled with hidden dangers. This research, like a seasoned camel caravan, sets out to explore the efficacy and safety of ranibizumab 0.5 mg, a treatment for macular edema (ME), a condition that can significantly impair vision. The study delves into the treatment of ME resulting from various causes, excluding those related to diabetes, retinal vein occlusion, or neovascular age-related macular degeneration.

A Journey to Improved Vision: Examining Treatment Effects

The study, like a carefully planned desert expedition, involved a double-masked, randomized, sham-controlled design. The findings indicate that ranibizumab 0.5 mg showed superior efficacy compared to sham treatment in improving best-corrected visual acuity (BCVA). This suggests that ranibizumab may offer a promising therapeutic option for patients with ME, potentially leading to improved vision and quality of life.

Navigating the Risks and Rewards: A Safety Assessment

The study also assessed the safety of ranibizumab 0.5 mg over a 12-month period. The results demonstrate that the treatment was well-tolerated, with no new safety concerns identified. This finding reinforces the importance of careful safety monitoring during clinical trials, ensuring the well-being of patients while exploring promising therapeutic options.

Dr.Camel's Conclusion

This research provides valuable insights into the treatment of macular edema, showcasing the potential benefits and safety of ranibizumab 0.5 mg. It highlights the importance of a thorough assessment of treatment efficacy and safety in clinical trials, ensuring that patients receive the best possible care while navigating the challenging desert of ophthalmic diseases. This study serves as a valuable guidepost, helping clinicians to make informed decisions about the use of ranibizumab for ME.

Date :
  1. Date Completed 2019-09-06
  2. Date Revised 2019-09-06
Further Info :

Pubmed ID

29371007

DOI: Digital Object Identifier

10.1016/j.ophtha.2017.12.002

Related Literature

Article Analysis
・Effective treatment of macular degeneration
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.